Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.48 |
| ▸ | MDM4 | O15151 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | FABP7 | O15540 | 1/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29398871 | 1.00 | CASP3 (0.52) | CASP3KMT2AEPHX2PIN1MDM4 | |
| SCHEMBL7317762 | 1.00 | CASP3 (0.52) | CASP3KMT2AEPHX2PIN1MDM4 | |
| SCHEMBL7390390 | 1.00 | CASP3 (0.52) | CASP3KMT2AEPHX2PIN1MDM4 | |
| SCHEMBL17256589 | 1.00 | CASP3 (0.52) | CASP3KMT2AEPHX2PIN1MDM4 | |
| SCHEMBL2591014 | 0.91 | CASP3 (0.58) | CASP3KMT2AEPHX2PIN1MDM4 | |
| SCHEMBL29670320 | 0.91 | CASP3 (0.58) | CASP3KMT2AEPHX2PIN1MDM4 | |
| SCHEMBL2591012 | 0.91 | CASP3 (0.58) | CASP3KMT2AEPHX2PIN1MDM4 | |
| SCHEMBL30725734 | 0.90 | CASP3 (0.52) | CASP3KMT2AEPHX2PIN1MDM4 | |
| SCHEMBL13722468 | 0.90 | CASP3 (0.52) | CASP3KMT2AEPHX2PIN1MDM4 | |
| SCHEMBL1486191 | 0.90 | CASP3 (0.54) | CASP3KMT2AEPHX2PIN1MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727552-A2 | PASSIVE PERMEABLE PCSK9 ANTAGONIST COMPOUNDS | Merck Sharp & Dohme LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| WO-2024259310-A2 | PASSIVE PERMEABLE PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2024-12-19 | — | — | WO | disclosed |
| US-20240156969-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEAGEN INC (US) | 2024-05-16 | — | — | US | disclosed |
| US-11793880-B2 | Conjugates of quaternized tubulysin compounds | SEAGEN INC. (US) | 2023-10-24 | — | — | US | disclosed |
| EP-4074328-A1 | INTERMEDIATES OF CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | Seagen Inc. (US) | 2022-10-19 | — | — | EP | disclosed |
| US-20220226482-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEAGEN INC (US) | 2022-07-21 | — | — | US | disclosed |
| EP-3383420-B1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEAGEN INC (US) | 2022-03-23 | — | — | EP | disclosed |
| US-11229708-B2 | Conjugates of quaternized tubulysin compounds | SEAGEN INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20190015517-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEATTLE GENETICS, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-8546533-B2 | Pipecolic linker and its use for chemistry on solid support | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2013-10-01 | — | — | US | disclosed |
| US-20110152464-A1 | PIPECOLIC LINKER AND ITS USE FOR CHEMISTRY ON SOLID SUPPORT | UNIVERSITE DE MONTPELLIER I (FR) | 2011-06-23 | — | — | US | disclosed |
| CN-101316852-A | Inhibitors of serine proteases | VERTEX PHARMA (US) | 2008-12-03 | — | — | CN | disclosed |
| US-6162824-A | NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | ALLELIX NEUROSCIENCE INC. | 2000-12-19 | — | — | US | disclosed |
| WO-1999041227-A1 | TRICYCLIC COMPOUNDS AS GLYCINE TRANSPORT INHIBITORS | ALLELIX NEUROSCIENCE, INC. (US) | 1999-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220226482-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | LCK, UACA, TEKT1 | CASP3 1499/4885KMT2A 2306/4885EPHX2 3384/4885 |
| US-11229708-B2 | Conjugates of quaternized tubulysin compounds | LCK, UACA, TEKT1 | CASP3 1499/4885KMT2A 2306/4885EPHX2 3384/4885 |
| US-20190015517-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | LCK, UACA, TEKT1 | CASP3 1499/4885KMT2A 2306/4885EPHX2 3384/4885 |
| US-20110152464-A1 | PIPECOLIC LINKER AND ITS USE FOR CHEMISTRY ON SOLID SUPPORT | PRRC2C, VIP, PRRC2A | CASP3 3929/4885KMT2A 4248/4885EPHX2 175/4885 |
| US-20240156969-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | LCK, UACA, TEKT1 | CASP3 1499/4885KMT2A 2306/4885EPHX2 3384/4885 |
| US-11793880-B2 | Conjugates of quaternized tubulysin compounds | LCK, UACA, TEKT1 | CASP3 1499/4885KMT2A 2306/4885EPHX2 3384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.